Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
|Articles|August 22, 2012
Providers: Make Long-Term Care a Priority in Health IT
Advertisement
Future federal incentive efforts for the use of electronic health-record systems and EHR design requirements need to focus on longitudinal care plans, transitions of care and patient assessments, post-acute care providers told federal health information technology officials.
Advertisement
Related to this article
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.
CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
3
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
4
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
5